06672nam 22007695 450 991029830930332120200630204749.03-642-39968-110.1007/978-3-642-39968-8(CKB)3710000000025248(EBL)1466316(OCoLC)862048947(SSID)ssj0001048999(PQKBManifestationID)11555658(PQKBTitleCode)TC0001048999(PQKBWorkID)11017501(PQKB)11666422(MiAaPQ)EBC1466316(DE-He213)978-3-642-39968-8(PPN)176114025(EXLCZ)99371000000002524820131004d2014 u| 0engur|n|---|||||txtccrAntimicrobials New and Old Molecules in the Fight Against Multi-resistant Bacteria /edited by Flavia Marinelli, Olga Genilloud1st ed. 2014.Berlin, Heidelberg :Springer Berlin Heidelberg :Imprint: Springer,2014.1 online resource (363 p.)Description based upon print version of record.3-642-39967-3 Includes bibliographical references and index.""Preface""; ""Contents""; ""Part ICurrent Trends in Antibiotics, Pathogens and Medical Needs""; ""1 The Origin and Evolution of Antibiotics""; ""Abstract""; ""1.1â€?Introduction""; ""1.2â€?Whatâ€?s in a Name?""; ""1.3â€?Many Sources, Uses, and Functions""; ""1.4â€?How Old Are â€?â€?Antibioticsâ€?â€??""; ""1.5â€?Antibiotic Myths""; ""1.6â€?Mode of Action and Evolution of Targets""; ""1.7â€?Parallel Chemical and Protein Evolution""; ""1.8â€?Conclusions""; ""References""""2 Novel Infectious Diseases and Emerging Gram-Positive Multi-Resistant Pathogens in Hospital and Community Acquired Infections""""Abstract""; ""2.1â€?Introduction""; ""2.2â€?Methicillin-Resistant S. aureus as a Cause of HospitalHospital- and Community-Acquired InfectionsCommunity-Acquired Infections""; ""2.3â€?Infections Caused by Glycopeptide-Resistant EnterococciEnterococci""; ""2.4â€?Issues with Clostridium difficileClostridium difficile Infections""; ""2.5â€?Conclusions""; ""3 Gram-Negative Pathogens: Overview of Novel and Emerging Resistant Pathogens and Drugs""; ""Abstract""""3.1â€?Introduction""""3.2â€?MDR, XDR and PDR Pathogens, and Resistance Mechanisms""; ""3.2.1 Resistance to beta -Lactam Antibiotics""; ""3.2.2 Resistance to Aminoglycosides""; ""3.2.3 Resistance to Tigecycline""; ""3.2.4 Resistance to Fluoroquinolones""; ""3.2.5 Resistance to Colistin""; ""3.2.6 Resistance to Phosphonic Acid Derivatives""; ""3.3â€?Emerging Gram-Negative Resistant Pathogens""; ""3.3.1 Pseudomonas aeruginosa""; ""3.3.1.1 Antibiotic Resistance Mechanisms""; ""3.3.1.2 Risk Factors for Infections and Resistance Development""; ""3.3.2 Acinetobacter baumannii""""3.3.2.1 Antibiotic Resistance Mechanisms""""3.3.2.2 Risk Factors for Infections and Resistance Development""; ""3.3.3 Enterobacteriaceae and Klebsiella pneumoniae""; ""3.3.3.1 Antibiotic Resistance Mechanisms""; ""3.3.3.2 Risk Factors for Infections and Resistance Development""; ""3.3.3.3 Klebsiella pneumoniae""; ""3.4â€?The Complexity of the Resistance Problem""; ""3.4.1 Novel Antimicrobials""; ""3.4.2 Novel beta -Lactam and beta -Lactamase Inhibitors""; ""3.4.2.1 Novel Cephalosporins""; ""3.4.2.2 Novel Carbapenems""; ""3.4.2.3 Novel Monobactams""""3.4.2.4 Novel beta -Lactamase Inhibitors""""3.4.3 Novel Non beta -Lactam Antibiotic Compounds""; ""3.4.3.1 Compounds Belonging to Known Class of Antimicrobial Agents""; ""3.4.3.2 Compounds Which Represent New Classes of Antimicrobials""; ""3.5â€?Conclusions""; ""References""; ""Part IIFamilies of Novel Candidates and Conventional Antibiotics""; ""4 The beta -Lactam Antibiotics: Their Future in the Face of Resistance""; ""Abstract""; ""4.1â€?Introduction""; ""4.2â€?Recent Advances in the Chemistry of the beta -Lactams""; ""4.2.1 New Cephalosporins""""4.2.1.1 Latest Generation Cephalosporins""Reports on the emergence and prevalence of resistant bacterial infections in hospitals and communities raise concerns that we may soon no longer be able to rely on antibiotics as a way to control infectious diseases. Effective medical care would require the constant introduction of novel antibiotics to keep up in the “arms race” with resistant pathogens. This book closely examines the latest developments in the field of antibacterial research and development. It starts with an overview of the growing prevalence of resistant Gram-positive and Gram-negative pathogens, including their various resistance mechanisms, prevalence, risk factors and therapeutic options. The focus then shifts to a comprehensive description of all major chemical classes with antibacterial properties, their chemistry, mode of action, and the generation of analogs; information that provides the basis for the design of improved molecules to defeat microbial infections and combat the emerging resistances. In closing, recently developed compounds already in clinical use, those in preclinical or first clinical studies, and a number of promising targets to be exploited in the discovery stage are discussed.Medical microbiologyDrug resistanceInfectious diseasesMicrobiologyMedical Microbiologyhttps://scigraph.springernature.com/ontologies/product-market-codes/B16003Drug Resistancehttps://scigraph.springernature.com/ontologies/product-market-codes/B16020Infectious Diseaseshttps://scigraph.springernature.com/ontologies/product-market-codes/H33096Applied Microbiologyhttps://scigraph.springernature.com/ontologies/product-market-codes/C12010Medical microbiology.Drug resistance.Infectious diseases.Microbiology.Medical Microbiology.Drug Resistance.Infectious Diseases.Applied Microbiology.610615.7616.9616.9041Marinelli Flaviaedthttp://id.loc.gov/vocabulary/relators/edtGenilloud Olgaedthttp://id.loc.gov/vocabulary/relators/edtBOOK9910298309303321Antimicrobials2502653UNINA